NCT00661375 - BAY43-9006 Phase II Study for Renal Cell Carcinoma | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions

Carcinoma, Renal Cell

Interventions

DRUG

Nexavar (Sorafenib, BAY43-9006)

BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.

Trial Locations (51)

466-8560

Nagoya

010-8543

Akita

289-2511

Asahi

260-0801

Chiba

260-8677

Chiba

791-0280

Matsuyama

812-0033

Fukuoka

812-8582

Fukuoka

830-0011

Kurume

372-0817

Isesaski

371-8511

Maebashi

003-0804

Sapporo

060-8543

Sapporo

060-8604

Sapporo

060-8648

Sapporo

073-0196

Sunagawa

305-8576

Tsukuba

020-8505

Morioka

761-0793

Kita

890-8520

Kagoshima

602-8566

Kyoto

606-8507

Kyoto

514-8507

Tsu

981-1293

Natori-shi

980-8574

Sendai

852-8501

Nagasaki

634-8522

Kashihara

951-8520

Niigata

710-8602

Kurashiki

700-8558

Okayama

537-8511

Osaka

589-8511

Sayama

565-0871

Suita

350-0495

Irima-gun

359-8513

Tokorozawa

431-3192

Hamamatsu

411-8777

Sunto

320-0834

Utsunomiya

770-8503

Tokushima

640-8558

Wakayama

641-8510

Wakayama

990-9585

Yamagata

755-8505

Ube

409-3898

Nakakoma

104-0045

Tokyo

113-8603

Tokyo

113-8655

Tokyo

116-8567

Tokyo

160-8582

Tokyo

162-8666

Tokyo

173-0003

Tokyo